Telehealth companies keep exposing their customers' medical data. What should they do?
The FTC sued Hims & Hers for allegedly disclosing customer health data, signing users up for hard-to-cancel subscriptions, and bypassing real-time doctor consultations. Hims disputes the claims. Experts note federal laws often don't apply to telehealth companies, leading to data sharing with advertisers. Recent studies found many telehealth services lack proper physician consultations, especially for GLP-1 drugs. State laws offer some protections, but enforcement is limited. Privacy experts reco
How this was made
The 30-second read
Why it matters
The lawsuit highlights a regulatory gap that could prompt new legislation, affecting the entire digital health ecosystem.
Market read
Regulatory risk for telehealth companies may drive short-term price pressure on Hims and raise sector-wide concerns.
What to watch
Potential for the company to settle quietly without admitting wrongdoing, limiting long-term impact.
Background
The FTC is expanding its enforcement against telehealth firms for privacy violations, citing Hims & Hers as a recent example.
Ticker impact
FTC filed a lawsuit alleging Hims & Hers disclosed customers' health data to Meta and other platforms.
Potential short-term downside as investors price in legal risk.
FTC lawsuits are material and often trigger stock declines, but the ultimate impact depends on settlement or court outcome.
Market effects
Increased scrutiny on the broader telehealth sector may affect peers like GoodRx and BetterHelp.
U.S. market may see heightened regulatory risk perception for digital health firms.
Regulatory precedent could influence international telehealth regulations.
Counterpoint
If the FTC's case stalls, Hims could emerge with minimal penalties, making the stock a potential rebound play.
Key entities
- RegulatorFederal Trade Commission
U.S. consumer protection agency filing the lawsuit.
- CompanyHims & Hers
Telehealth pioneer accused of sharing health data without consent.
